Day: November 4, 2024

• 135 patients enrolled TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Tigris Enrollment: Robust enrollment continues for 2024: 135 patients enrolled at end of October 2024 54 patients enrolled in 2024 so farvs. 31 patients enrolled in all of 2023 With 15 patients to target enrollment, the Company has entered the final push to fully enroll and finish the Tigris trial Based on current rate of enrollment, Management continues to estimate Tigris completion...

Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health authority approved pre-marketing early reimbursed access for B-VEC in France under the Accès Précoce (AP1) program; AP1 program for DEB patients access expected to start in 4Q 2024 Advancing Jeune Aesthetics’ KB301 to Phase 2 after positive results in Phase 1 Clinical updates on AATD and oncology program before end of year Strong balance sheet, ending the quarter with $694.2 million in cash and investments PITTSBURGH, Nov. 04, 2024 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today reported financial results and key business updates for the third quarter ending September 30,...

Introduces DNA Expand Subscription Platform to Enrich Existing DNA Ancestry Data with Comprehensive Health Insights GARDEN CITY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and diagnostics company, today announced the launch of DNA Complete, Inc., a wholly owned subsidiary, offering a groundbreaking direct-to-consumer DNA test that sequences virtually 100% of a customer’s genome. This new service provides customers with in-depth insights into health, wellness, and ancestry. DNA Complete – A New Paradigm in Direct-to-Consumer DNA Testing Comprehensive Whole Genome Sequencing: Unlike traditional DNA Ancestry tests that analyze small snippets of DNA, DNA Complete offers a full genomic view, empowering customers with detailed health and...

Analyst firm recognizes company’s streaming channel strength and demand facilitation expertise NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) — Magnite (NASDAQ: MGNI), the largest independent sell-side advertising company, was recognized with the highest score in the current offering category of the ten vendors evaluated in The Forrester Wave™: Sell-Side Platforms, Q4 2024 report. The report, authored by Forrester Senior Analyst Mo Allibhai, cites Magnite’s strength in streaming channels and demand facilitation expertise. In addition, Magnite received Forrester’s highest rating possible in 18 criteria, including Innovation, Desktop & Mobile Display, Open Standards & Transparency, Inventory Quality, and Deployment, Training & Ongoing Support. “More than ever, publishers need partners that have an eye to the future...

Supports Licensing Partner’s Phase 3 Activities in Acute Heart Failure WARRINGTON, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of an istaroxime patent for Hong Kong. The patent is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of AHF. The application number is 62021023600.1. The Notice of Publication of the Registration and Grant has a date of October 9,...

ORANGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) — Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the following conferences: UBS Global Healthcare Conference in Rancho Palos Verdes, California on Wednesday, Nov. 13, at 3:30 p.m. PST Stephens Annual Investment Conference in Nashville, Tennessee on Wednesday, Nov. 20, at 9 a.m. CST A webcast and replay of the presentations will be available on Alignment’s investor relations website at https://ir.alignmenthealth.com/. About Alignment HealthcareAlignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members...

North Carolina-based MLS contracts to make FOREWARN services available for its 7,000+ real estate professional members to promote proactive agent safety BOCA RATON, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) — FOREWARN, LLC, a red violet company (NASDAQ: RDVT) and the leading provider of real-time information solutions for real estate agents, today announced that Triad Multiple Listing Service (“Triad MLS”) will offer FOREWARN® services to the 7,000+ members they serve which include the Greensboro Regional REALTORS® Association, High Point Regional Association of REALTORS®, Winston-Salem Regional Association of REALTORS® and the surrounding areas to promote proactive real estate agent safety. Available both online and through a mobile application, FOREWARN analyzes billions of data points and provides users with the ability to mitigate...

MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) assigned the Barostim procedure to New Technology Ambulatory Payment Classification (APC) 1580. The APC payment of approximately $45,000 will continue in 2025, as published in the 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule. This follows the recent announcement that the American Medical Association CPT® Editorial Panel approved the application to transition Barostim from Category III to Category I CPT codes, expected to be implemented on January 1, 2026. Additionally, as previously announced, CMS reassigned Barostim to a higher paying MS-DRG for inpatient procedures effective October 1, 2024, increasing...

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) — Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the “Company” or “Entrée”) is pleased to provide analytical results for eight diamond drill holes (“DDH”) from the 2023 drilling program over the Hugo North Extension (“HNE”) deposit on the Entrée/Oyu Tolgoi JV Property (the “Entrée/Oyu Tolgoi JV Property”) in Mongolia (refer to Figure 1). Analytical results for 14 holes were previously announced on July 18, 2024. Results for eight remaining holes from the 2023 program, as well as all surface and underground holes from the ongoing 2024 drilling program, will be reported as they become available from the Company’s joint venture partner Oyu Tolgoi LLC (“OTLLC”). 2023 DRILL HOLE HIGHLIGHTS HNE Surface Drill Holes EGD 174: 448 metres (“m”) grading 1.62% copper equivalent1 (“CuEq”),...

Lifeward expects these actions to result in annual operating expense savings of approximately $3 million and gross margin improvement of 200 basis points during 2025 Consolidated real estate footprint will close two U.S. facilities to focus on operations in Massachusetts, Israel, and Germany MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) — Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), announced plans today to streamline its U.S. operations including the closing of two U.S. facilities to complete the integration that has followed the acquisition of AlterG in August 2023. The consolidation is expected to save the Company approximately $3 million in operating expenses and improve gross margins by approximately two percentage points when the full impact is achieved. Following the...